Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29307387 | 0.88 | TRPC6 (0.36) | KDM1AMAOAMAOBKMT2AMEN1 | |
| SCHEMBL4715480 | 0.86 | KMT2A (0.35) | KMT2AMEN1ALDH1A1MAPTPKM | |
| SCHEMBL1811563 | 0.84 | — | — | |
| SCHEMBL1813325 | 0.84 | — | — | |
| SCHEMBL1306991 | 0.84 | — | — | |
| SCHEMBL2675204 | 0.80 | HPGD (0.34) | KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL2372206 | 0.80 | HPGD (0.34) | KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL28109694 | 0.80 | HPGD (0.38) | KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL2874112 | 0.79 | DPP4 (0.44) | KDM1AMAOAMAOBKMT2AMEN1 | |
| SCHEMBL2552594 | 0.79 | KDM1A (0.41) | KDM1AMAOAMAOBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160317545-A1 | SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-11-03 | — | — | US | disclosed |
| WO-2011072791-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317545-A1 | SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | KDM1A 2643/4885MAOA 3509/4885MAOB 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.